A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS

A study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-07260437, a B7-H4 x CD3 bispecific mAb, in participants aged ≥18 years of age with advanced or metastatic breast cancer, ovarian cancer or endometrial cancer. Adult participants with other advanced or metastatic high B7-H4 expressing tumors may be considered after discussion with and approval from sponsor.

Start Date07 Oct 2021

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with PF-07260437

100 Translational Medicine associated with PF-07260437

100 Patents (Medical) associated with PF-07260437

Literatures (Medical) associated with PF-07260437

01 Nov 2015·Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition

[The Protective Effect of B7-H4 on Concanavalin A Induced Hepatic Injury in Mice].

Article

Author: Wang, Chao-qun ; Xu, Jun-fa ; Chen, Hong-yan ; Pan, Wei-min ; Xiao, Huan

OBJECTIVETo explore the protective effect and its mechanism of B7-H4 on the immuno hepatic injury.METHODSThe immuno hepatic injury was induced by Concanavalin A (Con A). Sixty KM mice were randomly divided into 4 groups with 15 mice in each group: Group A (saline), Group B (pcDNA3.1-mB7-H4-Fc), Group C (pcDNA3.1), Group D (Con A). One day before the injection of Con A (25 mg/kg), the mice in Group B and Group C received the injection of 100 pg pcDNA3.1-mB7-H4-Fc and 100 microg pcDNA3.1 respectively. The blood samples were collected at 12 h, 24 h and 48 h after Con A injection, the levels of ALT, AST, IL-4 and IFN-gamma were measured. Five mice in each group were sacrificed at the above 3 time points, the liver tissue were harvested for histopathological detection.RESULTSAfter Con A injection, the level of ALT in Group B, C, and D were higher than that in Group A. The level of ALT in Group B was lower than that in Group C and D. The significant difference was found between Group B and Group C. The hepatic injury of Group B was less serious than that of Group C and D.CONCLUSIONB7-H4 may have protection on the immune injury of liver induced by Con A.

100 Deals associated with PF-07260437

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	PR	Pfizer Inc.	07 Oct 2021
Advanced Malignant Solid Neoplasm	Phase 1	US	Pfizer Inc.	07 Oct 2021
Breast Cancer	Phase 1	PR	Pfizer Inc.	07 Oct 2021
Breast Cancer	Phase 1	US	Pfizer Inc.	07 Oct 2021
Endometrial Carcinoma	Phase 1	US	Pfizer Inc.	07 Oct 2021
Endometrial Carcinoma	Phase 1	PR	Pfizer Inc.	07 Oct 2021
Ovarian Cancer	Phase 1	PR	Pfizer Inc.	07 Oct 2021
Ovarian Cancer	Phase 1	US	Pfizer Inc.	07 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis